Endoscopic Findings in Patients Presented With Lower GIT Bleeding in Assiut University Hospitals, a Single-centre Study
1 other identifier
observational
110
0 countries
N/A
Brief Summary
Lower gastrointestinal bleeding (LGIB) refers to hematochezia or bright blood passing per rectum of colorectal source distal to ileocecal valve. This differs from the old definition of LGIB which involved small intestine distal to the ligament of Treitz. The new definition of LGIB aligns with current clinical practice and the reality that the majority of LGIB cases come from colorectal origin . In north America, LGIB is one fifth to one third as common as upper gastrointestinal bleeding (UGIB) and represents 30-40 % of all gastrointestinal bleeding cases . 20.5 - 27 cases per 100,000 adults are diagnosed to have LGIB with 21 to 40 cases per 100,000 adults are hospitalized . LGIB has a wide range of aetiologies, presentation and severity. The clinical picture of LGIB depends on patient's age, aetiology and associated comorbidities . Patients can present with overt bleeding in the form of hematochezia which is defined as passage of bright blood per rectum. This should be differentiated from melena (the passage of dark, offensive and digested blood with stool) associated with UGIB . However, 10-15 % of patients with severe acute UGIB can present with hematochezia . In addition, Occult LGIB can present in the form of iron deficiency anaemia or faecal occult bleeding . Causes of LGIB vary significantly according to patient age, lifestyle, dietary habits and geography or race. Some of the most common causes of LGIB include haemorrhoids, colorectal polyps, malignancy, colitis (infective, inflammatory, ischemic, etc.) as well as diverticular disease . However, there are limited data about the common causes of LGIB in upper Egypt.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Jul 2025
Typical duration for all trials
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
June 27, 2025
CompletedFirst Posted
Study publicly available on registry
July 18, 2025
CompletedStudy Start
First participant enrolled
July 25, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 30, 2027
ExpectedStudy Completion
Last participant's last visit for all outcomes
July 30, 2027
July 18, 2025
July 1, 2025
2 years
June 27, 2025
July 17, 2025
Conditions
Outcome Measures
Primary Outcomes (1)
Endoscopic detection of colorectal polyps according to paris classification
Paris Classification of Superficial GI Lesions Main Categories Type 0: Superficial Lesions Divided into 3 main types with subtypes: 1. Type 0-I: Protruded (Polypoid) 0-Ip (Pedunculated): Lesion is on a stalk (like a mushroom). 0-Is (Sessile): Broad-based elevation without a stalk. 2. Type 0-II: Non-Protruded, Non-Excavated (Flat) 0-IIa (Slightly Elevated): Slight elevation (less than 2.5 mm), often subtle. 0-IIb (Completely Flat): Same level as mucosa, hard to detect without special imaging (e.g., NBI). 0-IIc (Slightly Depressed): A shallow depression; higher risk for malignancy than IIa. 3. Type 0-III: Excavated (Ulcerated) True ulceration into the mucosa or deeper. Suggests deeper invasion and higher malignancy risk. Combined Morphologies Lesions can be mixed (e.g., 0-IIa + IIc, or 0-Is + IIa).
Within 24 hours after endoscopy procedure
Study Arms (1)
Patients presented with lower GI bleeding
Patients presented with lower GI bleeding will be investigated with endoscopy to detect different findings
Interventions
Upper Endoscopy and colonoscopy will be used
Eligibility Criteria
Patients presents with lower gastrointestinal bleeding
You may qualify if:
- patients with hematochezia and melena. -
You may not qualify if:
- poor bowel preparation.
- Inco-operative patients.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
MeSH Terms
Interventions
Intervention Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Resident doctor
Study Record Dates
First Submitted
June 27, 2025
First Posted
July 18, 2025
Study Start
July 25, 2025
Primary Completion (Estimated)
July 30, 2027
Study Completion (Estimated)
July 30, 2027
Last Updated
July 18, 2025
Record last verified: 2025-07